Provides information about the severity of renal cell cancer based on tumor, lymph node, and metastasis characteristics.
The TNM staging system offers an orderly progression of worsening prognosis estimates in most validation studies. There is controversy over some subcategories (e.g. T2a versus T2b) where estimates overlap, and the system has not, to our knowledge, been validated in populations treated with modern targeted therapies.
We are unaware of validated management algorithms using the score.
The TNM staging system is not proven to be accurate for individual survival prediction and should be considered a general guide rather than a reliable predictor.